Effect of the cytokine levels in serum on osteosarcoma

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1023-1028

  Xiao, Hong ^a   Chen, Ling ^a   Luo, Gang ^b   Son, Haihang ^c   Prectoni, James H ^c   Zheng, Wenjie ^b  

^a The 324th Hospital of the Chinese People's Liberation Army   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cytokine; Osteosarcoma; Serum

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CANCER RISK; CANCER SIZE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; TUMOR LOCALIZATION;

ADOLESCENT; CHILD; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; INTERLEUKIN-8; MALE; NEOPLASM METASTASIS; OSTEOSARCOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899107867     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1136-x     Document Type: Article

References (30)

1. Schwab JH, Springfield DS, Raskin KA, Mankin HJ, Hornicek FJ. What's new in primary bone tumors. J Bone Joint Surg Am. 2012;94:1913-9.
2. Szuhai K, Cleton-Jansen AM, Hogendoorn PC, Bovée JV. Molecular pathology and its diagnostic use in bone tumors. Cancer Genet. 2012;205:193-204.
3. Arndt CA, Rose PS, Folpe AL, Laack NN. Commonmusculoskeletal tumors of childhood and adolescence. Mayo Clin Proc. 2012;87:475-87.
4. Goldszmid RS, Trinchieri G. The price of immunity. Nat Immunol. 2012;13:932-8.
5. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol. 2012;24:633-97.
6. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 2012;122:3476-89.
7. Oliphant CJ, Barlow JL,McKenzie AN. Insights into the initiation of type 2 immune responses. Immunology. 2011;134:378-85.
8. Haddad H, Rini BI. Current treatment considerations in metastatic renal cell carcinoma. Curr Treat Options Oncol. 2012;13:212-29.
9. Keyel PA, Tkacheva OA, Larregina AT, Salter RD. Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol. 2012;189:4621-9.
10. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14:109-19.
11. Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J, et al.Gene expression of anti- and pro-apoptotic proteins inmalignant and normal plasma cells. Br J Haematol. 2009;145:45-58.
12. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735-41.
13. Zhou C, Shen Q, Xue J, Ji C, Chen J. Overexpression of TTRAP inhibits cell growth and induces apoptosis in osteosarcoma cells. BMB Rep. 2013;46:113-8.
14. Inoue T, Hagiyama M, Enoki E, Sakurai MA, Tan A, Wakayama T, et al. Cell adhesion molecule 1 is a new osteoblastic cell adhesion molecule and a diagnostic marker for osteosarcoma. Life Sci. 2013;92:91-9.
15. Shatz M, Menendez D, ResnickMA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 2012;72:3948-57.
16. Baumhoer D, Smida J, Zillmer S, Rosemann M, Atkinson MJ, Nelson PJ, et al. Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma. Mod Pathol. 2012;25:522-8.
17. Granowits E, Clark B, Mancilla J, Dinarello C. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem. 1991;266:14147-50. (Pubitemid 21907472)
18. McIntyre KW, Stepan GJ, Kolinsky KD, Benjamin WR, Plocinski JM, Kaffka KL, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med. 1991;173:931-9.
19. Dinarello CA. Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism. Int J Tissue React. 1992;14:65-75.
20. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27-55. (Pubitemid 28183358)
21. Hönicke AS, Ender SA, Radons J. Combined administration of EGCG and IL-1 receptor antagonist efficiently downregulates IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells. Int J Oncol. 2012;41:753-8.
22. Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol. 1993;50:15-9. (Pubitemid 23235504)
23. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 1993;120:1281-8. (Pubitemid 23064182)
24. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005;95:497-505. (Pubitemid 41420180)
25. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:1038-42.
26. Tang CH, Chen CF, Chen WM, Fong YC. IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells. J Biol Chem. 2011;286:11056-66.
27. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans-signaling in formation and progression ofmalignant ascites in ovarian cancer. Cancer Res. 2011;71:424-34.
28. Tzeng HE, Tsai CH, Chang ZL, Su CM, Wang SW, Hwang WL, et al. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma. Biochem Pharmacol. 2013;85:531-40.
29. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227:44-58.
30. Cordero JB, Macagno JP, Stefanatos RK, Strathdee KE, Cagan RL, Vidal M. Oncogenic ras diverts a host TNF tumor suppressor activity into tumor promoter. Dev Cell. 2010;18:999-1011.